Screener — stockrow

Vertex Pharmaceuticals Incorporated

VRTX Healthcare · Biotechnology · US

$547.43 +31.5% 1Y

Low $410.50 High $568.67

Vertex Pharmaceuticals is a biotechnology company that develops and sells medicines for serious diseases, focusing on specialty markets. Headquartered in Boston, it is led by chief executive Reshma Kewalramani.

Market cap $137.5B

Revenue growth (Q) +11.9%

EPS growth (Q) −39.0%

FCF growth (Q) −52.1%

Revenue growth (next yr) +10.4%

Net margin 30.7%

ROE 20.8%

P/E 34.9×

Forward P/E 38.2×

P/FCF 43.3×

Dividend yield —

Insider ownership 0.24%

Insider buys / sells (12M) — $158.1M

Reported	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	$8.9B	$9.9B	$11.0B	$12.0B	$13.0B
EPS	$12.82	$13.89	−$2.08	$15.32	$15.54
Free cash flow	$3.9B	$3.3B	−$978.0M	$3.2B	$3.2B
Net debt	−$10.3B	−$10.8B	−$6.0B	−$6.6B	−$2.8B

Moderna, Inc.

MRNA Healthcare · Biotechnology · US

$253.57 +942.2% 1Y

Low $22.28 High $267.50

Moderna is a biotechnology company based in Cambridge, led by chief executive Stéphane Bancel. It develops medicines using messenger RNA, or mRNA: instructions that direct the body’s cells to make proteins.

Market cap $96.4B

Revenue growth (Q) +29.2%

EPS growth (Q) +178.4%

FCF growth (Q) −90.9%

Revenue growth (next yr) +21.7%

Net margin −110.5%

ROE −34.5%

P/E —

Forward P/E −30.8×

P/FCF —

Dividend yield —

Insider ownership 8.93%

Insider buys / sells (12M) — $81.6M

Reported	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	$19.3B	$6.8B	$3.2B	$1.9B	$2.5B
EPS	$20.12	−$12.33	−$9.28	−$7.26	−$7.08
Free cash flow	$4.6B	−$3.8B	−$4.1B	−$2.1B	−$2.0B
Net debt	−$9.0B	−$8.0B	−$7.0B	−$5.2B	−$5.2B

Regeneron Pharmaceuticals, Inc.

REGN Healthcare · Biotechnology · US

$905.02 +39.9% 1Y

Low $591.52 High $991.73

Regeneron Pharmaceuticals is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Founded in 1988 and headquartered in Eastview, it is led by Chair, President and Chief Executive Officer Leonard S. Schleifer, M.D., Ph.D. The company’s approved medicines address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, blood conditions, infectious diseases, and rare diseases.

Market cap $93.4B

Revenue growth (Q) +36.3%

EPS growth (Q) +35.5%

FCF growth (Q) +3.85%

Revenue growth (next yr) +31.0%

Net margin 28.5%

ROE 15.0%

P/E 19.3×

Forward P/E 15.3×

P/FCF 25.4×

Dividend yield 0.41%

Insider ownership 2.11%

Insider buys / sells (12M) — $54.1M

Reported	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	$12.2B	$13.1B	$14.2B	$14.3B	$16.9B
EPS	$38.22	$34.77	$38.34	$41.48	$45.29
Free cash flow	$3.4B	$3.7B	$3.6B	$3.8B	$3.6B
Net debt	−$5.0B	−$8.1B	−$6.3B	−$5.9B	−$16.2B

argenex SE

ARGX Healthcare · Biotechnology · BE

$924.82 +8.67% 1Y

Low $661.85 High $1,072.75

argenx SE (ARGX) is a global biotechnology company founded in 2008 and headquartered in Breda, Netherlands, with additional offices in Ghent, Belgium, and Boston, USA. The company was established by a team of experienced scientists and entrepreneurs, including Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier. These founders aimed to leverage their expertise in immunology to develop innovative therapies for patients with severe autoimmune diseases and cancer.

Market cap $56.3B

Revenue growth (Q) +52.1%

EPS growth (Q) +50.6%

FCF growth (Q) +537.5%

Revenue growth (next yr) +51.1%

Net margin 31.7%

ROE 0.00%

P/E 30.6×

Forward P/E 30.1×

P/FCF 42.1×

Dividend yield —

Insider ownership 0.00%

Insider buys / sells (12M) — —

Reported	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	$445.3M	$1.3B	$2.3B	$4.2B	$5.9B
EPS	−$13.05	−$5.16	$12.78	$19.57	$28.66
Free cash flow	−$966.6M	−$464.1M	−$151.0M	$573.5M	$1.4B
Net debt	−$800.7M	−$2.0B	−$1.5B	−$3.5B	−$3.6B

BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare · Biotechnology · CH

$406.26 +22.2% 1Y

Low $253.95 High $410.71

BeOne Medicines discovers, develops and sells medicines for cancer. Founded in 2010, it is a Swiss-incorporated holding company whose operations are conducted mainly through subsidiaries in the United States, China, the United Kingdom and Australia.

Market cap $40.4B

Revenue growth (Q) +33.8%

EPS growth (Q) +144.1%

FCF growth (Q) +33.6%

Revenue growth (next yr) +26.6%

Net margin 13.9%

ROE 18.4%

P/E 68.9×

Forward P/E 47.7×

P/FCF 31.7×

Dividend yield —

Insider ownership 7.04%

Insider buys / sells (12M) — $391.3M

Reported	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	$1.4B	$2.5B	$3.8B	$5.3B	$6.6B
EPS	−$19.43	−$8.45	−$6.12	$2.53	$5.68
Free cash flow	−$1.8B	−$1.7B	−$638.0M	$921.7M	$1.4B
Net debt	−$4.0B	−$3.0B	−$2.5B	−$3.6B	−$5.0B

Stockrow Weekly